Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of FGFR1-MIP3 Alpha/Fc fusion protein in preparation of targeted anti-breast cancer drugs

A 1. FGFR1-MIP3, fusion protein technology, applied in the field of biomedicine, can solve the problems of insufficient targeted recruitment of DCs, poor tumor inhibitory activity, etc.

Pending Publication Date: 2018-12-21
THE FIRST AFFILIATED HOSPITAL OF HAINAN MEDICAL UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Recent studies on the application of Fc fusion proteins in tumors may bring new hope to us to solve the bottleneck problem of insufficient recruitment of targeted DCs and poor tumor suppressor activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of FGFR1-MIP3 Alpha/Fc fusion protein in preparation of targeted anti-breast cancer drugs
  • Application of FGFR1-MIP3 Alpha/Fc fusion protein in preparation of targeted anti-breast cancer drugs
  • Application of FGFR1-MIP3 Alpha/Fc fusion protein in preparation of targeted anti-breast cancer drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] 1. Materials, methods and experimental results

[0068] 1.1 Materials and methods

[0069] 1.1.1 Materials

[0070] The mouse FGFR1 / MIP3α-Fc, FGFR1-Fc, and MIP3α-Fc recombinant fusion proteins prepared by the research group were stored at 4°C for later use; Freund's complete adjuvant (F5881) and Freund's incomplete adjuvant (F5506) were purchased from SIGMA The company; 18-22g male BALB / c mice were provided by Hunan Slack Jingda Experimental Animal Co., Ltd. (experimental animal production license: SCXK (Xiang) 2016-0002); the mouse breast cancer 4T1 cell laboratory was kept.

[0071] Consumables such as cell culture flasks, freezing tubes, pipettes, centrifuge tubes, pipette tips, freezing boxes, and cell culture plates were purchased from Corning; DMEM medium and fetal calf serum (FCS) were purchased from Gibico BRL in the United States; Mouse PCNA antibody was purchased from Santa Cruz Company. FGFR1 monoclonal antibody (rat anti-mouse) was purchased from Santa Cr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of FGFR1-MIP3 Alpha / Fc fusion protein in the preparation of targeted anti-breast cancer drugs. The FGFR1-MIP3 Alpha / Fc fusion protein vaccine is discovered to be capable of obviously inhibiting the growth of 4T1 mouse breast cancer, the size of the tumor is obviously reduced, and the weight of the mouse and the weight of the tumor are obviously reduced; althoughthe FGFR1-Fc or MIP3 Alpha-Fc immunotherapy group has a certain degree of anti-tumor effect alone, the effect is not as good as the effect of the FGFR1-MIP3 Alpha group; and meanwhile, obvious toxic and side effects are not discovered in the process of experiment.

Description

technical field [0001] The invention relates to the use of FGFR1-MIP3α / Fc fusion protein in the preparation of targeted anti-breast cancer drugs, belonging to the technical field of biomedicine. Background technique [0002] Dendritic cell (DC) vaccine is the hotspot of tumor immunity research [1-3] . The function of DC is mainly to transport antigens through lymphatic vessels to migrate to lymph nodes after sensing peripheral danger signals, where they secrete cytokines that initiate immune responses and activate naive T cells into cytotoxic T lymphocytes and T helper cells, thereby forming adaptive Major mediators of the immune response, in addition they reduce immune repressors such as CD4 + CD25 + Foxp3 + The number of regulatory T cells (Treg), which is the immune cell with the strongest antigen-presenting function known so far [4-6] . There have been a large number of research reports on the anti-tumor therapeutic effect of DC vaccine, L et al showed the therap...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61P35/00
CPCA61K39/0011A61P35/00
Inventor 郑少江郭峻莉张晓钿黄用豪陈艳刘思汝吴新来
Owner THE FIRST AFFILIATED HOSPITAL OF HAINAN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com